Hennion & Walsh Asset Management Inc. Grows Stock Holdings in ImmunityBio, Inc. $IBRX

Hennion & Walsh Asset Management Inc. increased its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 31.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 402,639 shares of the company’s stock after buying an additional 95,855 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in ImmunityBio were worth $797,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of IBRX. Slow Capital Inc. bought a new position in shares of ImmunityBio in the third quarter worth about $25,000. Diversify Advisory Services LLC purchased a new stake in shares of ImmunityBio during the second quarter worth about $27,000. Truist Financial Corp bought a new stake in ImmunityBio during the 3rd quarter valued at approximately $27,000. Swiss Life Asset Management Ltd purchased a new position in ImmunityBio in the 3rd quarter worth approximately $27,000. Finally, Envision Financial Planning LLC purchased a new position in ImmunityBio in the 2nd quarter worth approximately $28,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. BTIG Research initiated coverage on shares of ImmunityBio in a report on Thursday, March 12th. They set a “buy” rating and a $13.00 price objective for the company. D. Boral Capital reissued a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a report on Monday, March 23rd. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. HC Wainwright lifted their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ImmunityBio presently has an average rating of “Moderate Buy” and an average price target of $14.40.

ImmunityBio Price Performance

Shares of IBRX opened at $7.30 on Friday. The stock has a market capitalization of $7.51 billion, a price-to-earnings ratio of -19.21 and a beta of 0.13. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $12.43. The business’s 50 day simple moving average is $7.74 and its 200-day simple moving average is $4.38.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. On average, sell-side analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Neutral Sentiment: Investment coverage shift: A Seeking Alpha author downgraded IBRX to Hold, arguing investors shouldn’t rush into buying amid current uncertainty. Read More.
• Negative Sentiment: Regulatory trigger cited by plaintiffs: Hagens Berman links the class action to an FDA warning over allegedly unsupported cancer‑treatment claims about Anktiva and says roughly $2B of market cap was erased. This FDA allegation is the core factual basis for many complaints and increases litigation risk and reputational damage. Read More.
• Negative Sentiment: Multiple law firms have filed or announced securities‑fraud suits and are soliciting lead plaintiffs (Robbins Geller, Kessler Topaz, Rosen, Pomerantz, Faruqi, DJS, Schall, Glancy, etc.), all alleging material misstatements/omissions about Anktiva during Jan. 19–Mar. 24, 2026. The proliferation of filings signals heightened class action exposure and potential aggregation of claims. Example filing/notice: Robbins Geller. Read More.
• Negative Sentiment: Solicitation & deadline notices continue: Multiple press releases and attorney announcements remind investors of the May 26, 2026 lead‑plaintiff deadline, increasing publicity and the likelihood of more claimants joining suits (examples: Rosen, PR Newswire). Read More.
• Negative Sentiment: Local/regional coverage amplifies reach: Additional alerts from firms (Kessler Topaz, Hagens Berman, Glancy, ClaimsFiler, DJS, Schall, etc.) broaden investor awareness and could increase short‑term selling pressure as legal risk and regulatory concerns are priced in. Read More.

Insiders Place Their Bets

In related news, Director Christobel Selecky sold 50,000 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of ImmunityBio stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares of the company’s stock, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 501,967 shares of company stock valued at $4,466,412 over the last three months. Corporate insiders own 69.48% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.